Wallerstedt Susanna
Sahlgrenska akademin - Göteborg, Sweden - Göteborg, Sweden.
Lakartidningen. 2016 Oct 18;113:D43D.
Medical and scientific assessments as the basis for prioritization and resource allocation for new drug treatment - experiences from five years of systematic workIn this study, the process for introduction of new drug treatment in Region Västra Götaland (second largest region in Sweden encompassing 1.6 million inhabitants, 17% of all inhabitants in Sweden) is described. A working group, consisting of persons with relevant expertise and declared conflicts of interest, contributes with medical and scientific assessments as the basis for prioritization and resource allocation. In 2011-2015, 111 new drug treatments were nominated by healthcare representatives, 84 fulfilled the criteria for assessments by the working group, and 57 (68%) were deemed to have high/medium high priority to receive introduction financing according to the severity of disease, the benefit/risk balance, and the level of evidence. When analyzing subsequent costs for new drug treatments for which data could be obtained and specifically evaluated, the results indicate that the process can contribute to rational use of medicines.
以医学和科学评估为基础进行新药治疗的优先排序和资源分配——五年系统性工作的经验
在本研究中,描述了瑞典西约塔兰地区(瑞典第二大地区,有160万居民,占瑞典总人口的17%)引入新药治疗的过程。一个由具有相关专业知识且声明存在利益冲突的人员组成的工作组,以医学和科学评估为依据,为优先排序和资源分配提供支持。在2011 - 2015年期间,医疗保健代表提名了111种新药治疗方案,其中84种符合工作组评估标准,根据疾病严重程度、获益/风险平衡以及证据水平,57种(68%)被认为具有高/中高优先级以获得引入资金。在分析可获取数据并进行具体评估的新药治疗的后续成本时,结果表明该过程有助于合理用药。